Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats

Journal of Neuroscience

Volumn 28, Issue 41, 2008, Pages 10422-10433

  Jones, Carrie K ^a,b   Brady, Ashley E ^a,b   Davis, Albert A ^e   Xiang, Zixiu ^a   Bubser, Michael ^b   Tantawy, Mohammed Noor ^c   Kane, Alexander S ^a   Bridges, Thomas M ^a   Kennedy, J Phillip ^b   Bradley, Stefania R ^d   Peterson, Todd E ^b,c   Ansari, M Sib ^b,c   Baldwin, Ronald M ^b,c   Kessler, Robert M ^b   Deutch, Ariel Y ^a,b   Lah, James J ^e   Levey, Allan I ^e   Lindsley, Craig W ^a,b   Conn, P Jeffrey ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d ACADIA PHARMACEUTICALS INC   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; M1 allosteric agonist; mAChR; Muscarinic acetylcholine receptors; Schizophrenia; TBPB

Indexed keywords

[1 (1' 2 METHYLBENZYL 1,4' BIPIPERIDIN 4 YL) 1H BENZO[D]IMIDAZOL 2(3H) ONE]; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; 1 (1' (2 METHYLBENZYL) 1,4' BIPIPERIDIN 4 YL) 1H BENZO(D)IMIDAZOL 2 (3H) ONE; 1-(1'-(2-METHYLBENZYL)-1,4'-BIPIPERIDIN-4-YL)-1H-BENZO(D)IMIDAZOL-2-(3H)-ONE; AMYLOID; AMYLOID PRECURSOR PROTEIN; BENZIMIDAZOLE DERIVATIVE; DOPAMINE 2 RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; PIPERIDINE DERIVATIVE;

ALLOSTERISM; ANIMAL CELL; ARTICLE; BRAIN REGION; COGNITION; CONTROLLED STUDY; DRUG MECHANISM; HIPPOCAMPUS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SYNAPTIC TRANSMISSION; ANIMAL; BINDING SITE; CHEMISTRY; CHO CELL; CRICETULUS; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; ELECTRIC CONDUCTIVITY; GENETIC TRANSFECTION; HAMSTER; IN VITRO STUDY; METABOLISM; PATCH CLAMP; PHYSIOLOGY; PROTEIN PROCESSING; PYRAMIDAL NERVE CELL; SPRAGUE DAWLEY RAT;

ALLOSTERIC SITE; AMYLOID; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZIMIDAZOLES; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC CONDUCTIVITY; HIPPOCAMPUS; MALE; PATCH-CLAMP TECHNIQUES; PIPERIDINES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRAMIDAL CELLS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, MUSCARINIC M1; RECEPTORS, DOPAMINE D2; RECEPTORS, N-METHYL-D-ASPARTATE; SYNAPTIC TRANSMISSION; TRANSFECTION;

EID: 55249118679     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.1850-08.2008     Document Type: Article

References (50)

1. Anagnostaras SG, Murphy GG, Hamilton SE, Mitchell SL, Rahnama NP, Nathanson NM, Silva AJ (2003) Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 6:51-58.
2. 18F]fallypride methods intended for automated remote chemistry modules. J Nucl Med 47:159P.
3. Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymaster FP, Hurley DJ, Potter WZ, Paul SM (1997a) Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 54:465-473.
4. Bodick NC, Offen WW, Shannon HE, Satterwhite J, Lucas R, van Lier R, Paul SM (1997b) The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease. Alzheimer Dis Assoc Disord 11 [Suppl 4]:S16-S22.
5. Bonner TI, Buckley NJ, Young AC, Brann MR (1987) Identification of a family of muscarinic acetylcholine receptor genes. Science 237:527-532.
6. Bonner TI, Young AC, Brann MR, Buckley NJ (1988) Cloning and expression of the human and rat m5 muscarinic acetylcholine receptor genes. Neuron 1:403-410.
7. Bubser M, Deutch AY (2002) Differential effects of typical and atypical antipsychotic drugs on striosome and matrix compartments of the striatum. Eur J Neurosci 15:713-720.
8. Bymaster FP, Carter PA, Peters SC, Zhang W, Ward JS, Mitch CH, Calligaro DO, Whitesitt CA, DeLapp N, Shannon HE, Rimvall K, Jeppesen L, Sheardown MJ, Fink-Jensen A, Sauerberg P (1998) Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects. Brain Res 795:179-190.
9. Caccamo A, Oddo S, Billings LM, Green KN, Martinez-Coria H, Fisher A, LaFerla FM (2006) M1 receptors play a cnetral role in modulating AD-like pathology in transgenic mice. Neuron 49:671-682.
10. Christopoulos A (2002) Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov 1:198-210.
11. Coyle JT, Tsai G, Goff DC (2002) Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Curr Drug Target CNS Neurol Disord 1:183-189.
12. Cummings JL, Nadel A, Masterman D, Cyrus PA (2001) Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease. J Geriatr Psychiatry Neurol 14:101-108.
13. Deutch AY (1994) Identification of the neural systems subserving the actions of clozapine: clues from immediate-early gene expression. J Clin Psychiatry 55 [Suppl B]:37-42.
14. Eglen RM, Choppin A, Watson N (2001) Therapeutic opportunities from muscarinic research. Trends Pharmacol Sci 22:409-414.
15. Felder CC, Porter AC, Skillman TL, Zhang L, Bymaster FP, Nathanson NM, Hamilton SE, Gomeza J, Wess J, McKinzie DL (2001) Elucidating the role of muscarinic receptors in psychosis. Life Sci 68:2605-2613.
16. Fibiger HC (1994) Neuroanatomical targets of neuroleptic drugs as revealed by Fos immunochemistry. J Clin Psychiatry 55 [Suppl B]:33-36.
17. Gerber DJ, Sotnikova TD, Gainetdinov RR, Huang SY, Caron MG, Tonegawa S (2001) Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc Natl Acad Sci U S A 98:15312-15317.
18. Geyer MA, Ellenbroek B (2003) Animal behavior models of the mechanisms underlying antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 7:1071-1107.
19. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356.
20. Hemstapat K, Da Costa H, Nong Y, Brady AE, Luo Q, Niswender CM, Tamagnan GD, Conn PJ (2007) A novel family of potent negative allosteric modulators of group II metabotropic glutamate receptors. J Pharmacol Exp Ther 322:254-264.
21. Irwin S (1968) Comprehensive observational assessment: IA. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia 13:222-257.
22. Jones CK, Brady AE, Bubser M, Deutch AY, Williams LC et al (2006) TBPB is a highly selective M1 allosteric muscarinic receptor agonist in vitro and produces robust antipsychotic-like effects in vivo. Neuropsychopharmacology 31:S116.
23. 2 receptors. Synapse 15:169-176.
24. Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, et al (2005) Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol. Neuropsychopharmacology 30:2283-2289.
25. Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, Meltzer HY (2006) Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology 31:1991-2001.
26. Kinney GG (2006) Muscarinic receptor activation for the treatment of schizophrenia. Neuropsychopharmacology 31:S26.
27. Levey AI, Kitt CA, Simonds WF, Price DL, Brann MR (1991) Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J Neurosci 11:3218-3226.
28. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL (1996) Distribution volume ratios without blood sampling from graphical analysis and PET data. J Cereb Blood Flow Metab 16:834-840.
29. Marino MJ, Conn PJ (2002) Direct and indirect modulation of the N-methyl D-aspartate receptor. Curr Drug Target CNS Neurol Disord 1:1-16.
30. Marino MJ, Rouse ST, Levey AI, Potter LT, Conn PJ (1998) Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl- D-aspartate (NMDA) receptor currents in hippocampal pyramidal cells. Proc Natl Acad Sci U S A 95:11465-11470.
31. Moore NA, Tye NC, Axton MS, Risius FC (1992) The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 262:545-551.
32. Mukherjee J, Christian BT, Narayanan TK Shi B, Mantil J (2001) Evaluation of dopamine D-2 receptor occupancy by clozapine, risperidone, and haloperidol in vivo in the rodent and nonhuman primate brain using 18F-fallypride. Neuropsychopharmacology 25:476-488.
33. Perry KW, Nisenbaum LK, George CA, Shannon HE, Felder CC, Bymaster FP (2001) The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex. Biol Psychiatry 49:716-725.
34. Reynolds GP (2004) Receptor mechanisms in the treatment of schizophrenia. J Psychopharmacol 18:340-345.
35. Rodriguez AL, Nong Y, Sekaran NK, Alagille D, Tamagnan GD, Conn PJ (2005) Aclose structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators. Mol Pharmacol 68:1793-1802.
36. Rouse ST, Marino MJ, Potter LT, Conn PJ, Levey AI (1999) Muscarinic receptor subtypes involved in hippocampal circuits. Life Sci 64:501-509.
37. Shannon HE, Rasmussen K, Bymaster FP, Hart JC, Peters SC, Swedberg MD, Jeppesen L, Sheardown MJ, Sauerberg P, Fink-Jensen A (2000) Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophr Res 42:249-259.
38. Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dubé S, Mallinckrodt C, Bymaster FP, McKinzie DL, Felder CC (2008) Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 165:1033-1039.
39. Shirey JK, Xiang Z, Orton D, Brady AE, Johnson KA, Williams R, Ayala JE, Rodriguez AL, Wess J, Weaver D, Niswender CM, Conn PJ (2008) An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Nat Chem Biol 4:42-50.
40. Spalding TA, Trotter C, Skjaerbaek N, Messier TL, Currier EA, Burstein ES, Li D, Hacksell U, Brann MR (2002) Discovery of an ectopic activation site on the M(1) muscarinic receptor. Mol Pharmacol 61:1297-1302.
41. Spalding TA, Ma JN, Ott TR, Friberg M, Bajpai A, Bradley SR, Davis RE, Brann MR, Burstein ES (2006) Structural requirements of transmembrane domain 3 for activation by the M1 muscarinic receptor agonists AC-42, AC-260584, clozapine, and N-desmethylclozapine: evidence for three distinct modes of receptor activation. Mol Pharmacol 70:1974-1983.
42. Sorbera LA, Bozzo J, Serradell N (2007) Alzheimer's disease one century later: the search for effective therapeutic targets continues. Drugs Future 32:625-641.
43. Stanhope KJ, Mirza NR, Bickerdike MJ, Bright JL, Harrington NR, Hesselink MB, Kennett GA, Lightowler S, Sheardown MJ, Syed R, Upton RL, Wadsworth G, Weiss SM, Wyatt A (2001) The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. J Pharmacol Exp Ther 299:782-792.
44. Sur C, Mallorga PJ, Wittmann M, Jacobson MA, Pascarella D, Williams JB, Brandish PE, Pettibone DJ, Scolnick EM, Conn PJ (2003) N-Desmethylclozapine, a novel allosteric agonist at muscarinic 1 receptor potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci U S A 100:13674-13679.
45. 18F]Fallypride binding potential with delayed scans. Presented at the 54th Annual Meeting of the Society of Nuclear Medicine, Washington, DC, June 2-6.
46. Tarsy D, Simon DK (2006) Dystonia. N Engl J Med 335:818-829.
47. Waelbroeck M (2003) Allosteric drugs acting at muscarinic acetylcholine receptors. Neurochem Res 28:419-422.
48. Weiner DM, Meltzer HY, Veinbergs I, Donohue EM, Spalding TA, et al (2004) The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine. Psychopharmacology 177:207-216.
49. Young CD, Bubser M, Meltzer HY, Deutch AY (1999) Clozapine pretreatment modifies haloperidol-elicited forebrain Fos induction: a regionally-specific double dissociation. Psychopharmacology 144:255-263.
50. 5 muscarinic receptor knock-out mice. J Neurosci 22:6347-6352.